AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies for Crohn’s Disease

Shots:

  • The P-III ADVANCE & MOTIVATE studies involves assessing of Risankizumab (600/1200mg) vs PBO in adult patients with mod. to sev. CD who had an inadequate response/ were intolerant to conventional and/or biologic therapy & patients who had responded inadequately or were intolerant to biologic therapy respectively
  • Results: @12wks. clinical remission as per CDAI (45%/42% vs 25%) & (42%/41% vs 19%); clinical remission per PRO-2 (43%/41% vs 21%) & (35%/39% vs 19%); endoscopic response (40%/32% vs 12%) & (29%/34% vs 11%) respectively
  • Skyrizi is an IL-23 inhibitor, being evaluated in mod. to sev. CD and other immune-mediated conditions

Click here ­to­ read full press release/ article | Ref: AbbVie| Image: Law.com

The post AbbVie Reports Results of Skyrizi (risankizumab) in P-III Induction Studies for Crohn’s Disease first appeared on PharmaShots.

Microsoft Collaborates with Twist and Illumina to Advance Data Storage in DNA

Shots:

  • Microsoft enters collaboration with Illumina, Twist, and Western Digital to establish a roadmap for the industry towards the wider use of DNA data storage. These companies are the founding members of the alliance
  • Ten additional technology leaders join founding members to together advance industry roadmap, set the stage for widespread adoption of new long-term storage option
  • The alliance announced at the virtual Flash Memory Summit, focus to set technology & formatting standards with the goal of building interoperable commercial systems capable of housing the exponential amounts of data expected to be generated in the future

Click here­ to­ read full press release/ article | Ref: Businesswire | Image: DNA Stack

The post Microsoft Collaborates with Twist and Illumina to Advance Data Storage in DNA first appeared on PharmaShots.

Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19

Shots:

  • The companies reported the preclinical results of MRT5500 demonstrating the potential of the vaccine in neutralizing the Abs against SARS-CoV-2. The two doses of MRT5500 induced neutralizing antibody levels significantly higher than those observed in COVID-19 patients
  • The preclinical data support the advancement of MRT5500 for clinical development. The companies anticipate the initiation of P-I/II study in Q4’20
  • MRT5500 is being developed under the collaboration between Sanofi Pasteur and Translate Bio and has demonstrated its ability to elicit an immune response in both mice and non-human primates in a preclinical study

Click here ­to­ read full press release/ article | Ref: Sanofi | Image: Business Line

The post Sanofi and Translate Bio to Advance MRT5500 into Clinical Study Against COVID-19 first appeared on PharmaShots.

AstraZeneca Collaborates with Eko to Advance the Digital Health Tools for the Diagnosis of CV Diseases

Shots:

  • The two companies collaborated to facilitate the development of digital health tools for the earlier screening of cardiovascular diseases, including HF
  • AstraZeneca and Eko will accelerate the development of Eko algorithms, enhancing clinical trials with Eko technology, and potentially building new HF detection solutions. The agreement allows the companies to harness the potential to improve access to individualized care and generate better patient outcomes
  • In Dec’2019, Eko has received the US FDA’s BT designation for a novel ECG-based algorithm that can identify reduced LVEF. If approved, the algorithm will be compatible with the DUO, Eko’s handheld stethoscope, and ECG device

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Physician Practice




Baxter and Ayogo Expand their Partnership to Advance Digital Health Solution for Home Dialysis

Shots:

  • The companies expanded the collaboration to support the needs of patients with kidney disease via digital health solutions. The agreement integrates Ayogo’s LifePlan digital platform with Baxter’s expertise in renal care to develop mobile apps and digital solutions that bring personalized and timely support to patients with kidney failure
  • Baxter made an equity investment in Ayogo in exchange for a minority interest in the company. The new initiative will provide patients the ability to proactively manage their home dialysis therapy records in collaboration with their healthcare team
  • Earlier, the two companies collaborated to develop a patient engagement app, CKD&Me that provides customized disease and therapy education for the learning needs of patients with CKD. The companies have launched the app in the US and are preparing to expand it globally

Click here ­to­ read full press release/ article | Ref: Baxter | Image: StraitTimes